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Abstract 
 
OBJECTIVE: The objective of this selective EBM review is to determine whether or not “Is the 
combination therapy of clopidogrel (Plavix) and aspirin compared to antithrombotic single 
therapy is safe and effective in the prevention of stroke in adults?”   	  
STUDY	  DESIGN:	  Review	  of	  three,	  English	  language,	  double-­‐blinded,	  randomized	  controlled	  trial	  studies	  with	  an	  intention-­‐to-­‐treat	  basis	  published	  in	  2004-­‐2010.	  	  
DATA	  SOURCES:	  	  Three	  randomized	  controlled	  trial	  studying	  the	  safety	  and	  effectiveness	  of	  the	  combination	  therapy	  of	  clopidogrel	  (Plavix)	  and	  Aspirin	  compared	  to	  antithrombotic	  single	  therapy	  in	  the	  prevention	  of	  stroke	  in	  adults.	  	  
OUTCOME	  (S)	  MEASURED:	  	  Outcomes	  measured	  were	  prevention	  of	  stroke,	  which	  was	  measured	  by	  randomly	  assigned	  patients	  with	  evident	  cardiovascular	  disease	  or	  multiple	  risk	  factors	  who	  received	  clopidogrel	  plus	  low	  dose	  aspirin	  or	  placebo	  plus	  low	  dose	  antithrombotic.	  These	  were	  then	  followed	  during	  a	  28-­‐month	  period	  while	  observing	  the	  number	  of	  strokes	  that	  occurred	  within	  that	  time	  period,	  life-­‐threatening	  or	  major	  bleeding	  occurrences.	  	  Severity	  of	  stroke	  in	  one	  study	  was	  measured	  with	  mRS	  score	  at	  3	  months	  after	  the	  stroke	  in	  one	  study.	  The	  (mRS)	  Modified	  Rankin	  Scale	  is	  defined	  as	  the	  functional	  severity	  of	  the	  first	  stroke	  outcome	  event	  at	  3	  months	  after	  the	  event.	  It	  is	  measured	  by	  assessing	  all	  ADLs	  patients	  could	  actually	  do	  (waking,	  bathing,	  dressing,	  grooming)	  after	  a	  stroke.	  Data	  was	  analyzed	  on	  an	  intention-­‐to-­‐treat	  basis.	  The	  other	  two	  studies	  measured	  the	  risk	  of	  life-­‐threatening	  or	  major	  bleeding	  by	  the	  number	  of	  occurrences	  during	  a	  28	  month	  follow	  up.	  	  	  
RESULTS:	  	  The	  articles	  reviewed	  showed	  that	  there	  was	  no	  significant	  benefit	  associated	  with	  clopidogrel	  (Plavix)	  plus	  aspirin	  as	  compared	  with	  antithrombotic	  single	  therapy	  in	  reducing	  the	  incidence	  of	  stroke.	  Furthermore,	  in	  the	  article	  by	  Bhatt	  showed	  how	  the	  risk	  of	  moderate	  –to-­‐severe	  bleeding	  was	  increased	  	  	  
CONCLUSION:	  Based	  on	  the	  articles	  reviewed,	  the	  difference	  between	  clopidogrel	  and	  aspirin	  was	  not	  statistically	  significant	  or	  more	  effective	  than	  single	  antithrombotic	  therapy	  alone	  in	  reducing	  the	  rate	  of	  stroke.	  	  Furthermore	  the	  use	  of	  combination	  therapy	  increased	  the	  risk	  of	  moderate	  to	  severe	  bleeding.	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INTRODUCTION	  
Stroke is an acute neurologic injury that occurs as a result of either ischemia due to thrombosis, 
embolism or systemic hypoperfusion or due to brain hemorrhage. Approximately 80 percent of 
strokes are due to ischemic cerebral infarction and the remaining 20 percent to brain hemorrhage. 
Ischemic stroke is known to be caused by the occlusion of an intracranial vessel that causes 
diminished supply of arterial blood resulting in ischemia and a lack of oxygen and glucose to 
brain tissue. Of the three subtypes of brain ischemia thrombosis generally refers to local in situ 
obstruction of an artery due to disease of the arterial wall for example atherosclerosis. Embolism 
can result from debris originating from elsewhere for example those with atrial fibrillation. 
Ischemic stroke may occur in patients with atrial fibrillation either as an initial presenting 
manifestation of atrial fibrillation or despite antithrombotic prophylaxis. Cardiac embolis most 
commonly originate from the left atrium, which lead to ischemia and systemic hypoperfusion.4   
The patient often has a history of hypertension, diabetes mellitus, valvular heart disease or 
atherosclerosis.  
The symptoms of brain ischemia may be transient; lasting seconds to minutes, or may persist for 
longer periods of time. Signs and symptoms of stroke unfortunately remain indefinitely if the 
brain becomes irreversibly damaged and infarction occurs. Unfortunately patient’s neurological 
symptoms do not necessarily reflect the presence or the absence of infarction and the symptoms 
may not indicate the cause of the ischemia that leads to stroke. It is therefore critical for 
providers to accurately identify the cause of the symptoms because treatment as well as 
prevention depends upon accurately identifying the cause of symptoms.4 The impact of stroke 
can be devastating affecting physical, cognitive, emotional function and lifestyle.  
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Stroke causes mortality in almost 130, 000 Americans each year which comes to 1 in 
every 19 deaths. The number of stroke deaths is projected to double by 2030 due to the increase 
in the elderly population. Approximately 87 % of strokes are ischemic with the remaining 13% 
being hemorrhagic therefore the prevalence being so high crosses over into various scopes of the 
PA areas of practice and it is vital for providers not only to accurately treat but also prevent the 
incidence of stroke. 5,6 According to the Center for Disease Control stroke costs the United States 
and estimated $38.6 billion each year. This total includes the cost of health care services, 
medications, and missed days of work. Unfortunately there have not been any current studies 
done for hospitalizations within the last few years for stroke although past studies from the CDC 
showed an increase from 1989 having 800,000 as compared to 1999 and 2009 which both had 
almost 1 million. Hospitalizations were for patients who were 65 years and older. 5 
In instances of acute stroke patients are treated with thrombolytics if symptoms are within three 
hours of onset and hemorrhagic stroke has been ruled out by a CT scan.  Anticoagulation is the 
most effective long-term antithrombotic therapy for the prevention of recurrent stroke. Currently 
Warfarin is the most studied antithrombotic therapy for the prevention of stroke in patients with 
atrial fibrillation and an ischemic stroke and its efficacy is well demonstrated. Warfarin acts by 
inhibiting a vitamin K complex that required for coagulation factors therefore by depleting 
functional vitamin K reserves warfarin reduces synthesis of active clotting factors. Patients are 
required to continually have their INR monitored once placed on warfarin.  Dual antiplatelet 
therapy has also been studied to be a reasonable alternative to therapy with 4 Aspirin having a  
mechanism of action that works by irreversibly inhibiting cyclooxygenase-1 and 2 (COX1and2) 
enzymes via acetylation which eventually causes inhibition of platelet aggregation. Clopidogrel 
functions by blocking receptors on the platelet surface which prevents activation of the 
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GPIIb/IIIa receptor complex thereby reducing platelet aggregation. Current research and data has 
shown low dose aspirin to reduce ischemic outcomes and recurrence in patients and clopidogrel 
(Plavix) has been also studied separately to reduce stroke recurrence rate by 30 percent.  
OBJECTIVE 
The objective of this selective EBM review is to determine whether or not “ Is the combination 
therapy of clopidogrel (Plavix) and Aspirin compared to antithrombotic single therapy safe and 
effective in the prevention of stroke in adults” 
METHODS 
 A detailed study was completed by the author using key words clopidogrel (Plavix), 
Aspirin and stroke. The articles that were used focused primarily on outcomes of importance to 
the patient (Patient Oriented Evidence that matters, or POEMS). The search engines used were 
via PubMed and all articles were published in English and all were published in peer-reviewed 
journals.  Randomized control trials were searched for the following inclusion criteria: Patients 
between the ages of 18 and older who have had one of the following: Multiple atherothrombotic 
risk factors, documented coronary disease, high risk vascular patients who experienced at least 
one previous TIA or an ischemic stroke. A total of three studies were used that were all 
randomized, double-blinded controlled trial with an intention to treat bases and one study being a 
multicenter multinational study. These compared the combination therapy of clopidogrel and 
aspirin to a single antithrombotic therapy or to aspirin alone.  The standard dosage of 75mg of 
clopidogrel was used in all three studies with low dose aspirin dose varying from 75 to 162mg 
per day or placebo plus low dose aspirin. There were also certain exclusion criteria of patients 
who had severe comorbid conditions, increased risk of bleeding with clinical evidence of severe 
hepatic insufficiency, current peptic ulceration, history of symptomatic bleeding. Table 1 
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demonstrates the demographics or the studies included:  Statistics were reported using p-values, 
relative risk increase (RRI), absolute risk increase (ARI) and number needed to harm (NNH). 
OUTCOMES MEASURED 
 The outcomes measured in all three studies analyzed the overall intervention of 
clopidogrel and aspirin compared to a single antithrombotic therapy such as aspirin alone or 
other antiplatelet agent.  Follow up evaluations were performed in the Bhatt article at one month, 
three months, and six months and every six months thereafter until the end of the trial. Data in 
this trial was analyzed on an intention –treat basis. In the article by Hankey outcomes were 
measured using the Modified Rankin scale  (mRS) score, which was assessed by incorporating 
all the activities the patients could do 3 months after having a stroke. These activities included 
patients having the ability to walk, bathe, dress and groom themselves.  Data was also analyzed 
with an intention to treat basis. In the article by Diener the outcome was measured by the first 
occurrence of an event as an ischemic stroke during an 18 month follow up period a scheduled at 
1,3,6,12, and 18 month follow up. The outcome for life-threatening bleeding was also measured 
at the same times. This was defined as a drop in hemoglobin of greater than 50g/L, significant 
hypotension with need for inotropes, symptomatic intracranial hemorrhage or a transfusion of 
less than 3 units of red-blood cells or equivalent amount of whole blood. In all three studies 
analysis was based on first occurrence of an ischemic event at any period during the follow-up 
period. Several covariables including age, sex and ethnic origin for potential effects on the 
primary endpoint including possible interactions with treatment were regarded.  This paper 
evaluates the intervention of the combination of clopidogrel and aspirin in altering the rate and 
functional severity of stroke among high risk patients using number of occurrences during a 28 
month follow-up period. 
 Table 1: Demographics & Characteristics of included studies  
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Study  Type  #Pts  Age 
(yrs) 
Inclusion 
Criteria 
Exclusion 
Criteria 
W/D Interventions  
Bhatt 
2006 
Randomized
,double 
blinded, 
placebo-
controlled 
trial 
15, 603 > 45 
years 
Adults > 45 
years or older 
with either 
clinically 
evident 
cardiovascular 
disease or 
multiple risk 
factors 
including 
stroke 
-Patients taking 
oral 
antithrombotic 
medication or 
NSAIDs on a 
long-term basis 
(cox2 inhibitors 
were permitted) 
-Indications for 
clopidogrel 
therapy such as 
recent acute 
coronary 
syndrome 
- vascularization 
0 Regimen to 
receive 
clopidogrel 
(75mg per 
day) plus 
low dose 
Aspirin (75-
162mg per 
day) or to 
receive 
placebo plus 
low-dose 
aspirin 
Diener 
HC 
2004 
Randomized
, double 
blinded, 
placebo 
controlled 
trial 
7599 18- 75 
years 
Ischemic stroke 
or TIA in 
previous 3 
months and 
had 1 or more 
of the 
additional risk 
factors: 
Previous 
ischemic 
stroke, MI, 
angina 
perctoris 
DM, 
symptomatic 
peripheral 
artery disease; 
all of the above 
within the last 
3 years 
Contraindicated 
for aspirin or 
clopidogrel 
Age <40 years 
Severe comorbid 
conditions 
Incresed risk of 
bleeding (clinical 
evidence of 
severe hepatic 
insufficiency) 
History of 
systemic bleeding 
Other history of 
bleeding, 
diathresis or 
coagulopathy 
Scheduled for 
major surgery or 
vascular surgery 
270 
disc
onti
nued 
treat
men
t  
Regimen of 
Aspirin (75 
mg/per day) 
and 
clopidogrel 
(75mg 
per/day) or 
receive 
placebo and 
clopidogrel 
(75mg) 
Hankey 
GJ 
2010 
Multicenter, 
multinationa
l, 
Randomized
, parallel 
group, 
double 
blinded trial 
15, 603 65 +/- 
10 
years 
Age 65 +/- 10 
all high 
vascular risk 
patients who 
experienced at 
least 1 previous 
TIA or 
ischemic stroke 
- diagnosis of 
documented 
cerebrovascular 
disease 
Patients 65 +/- 10 
yrs with a 
previous 
disabling 
condition such 
that they were 
bedridden or 
demented were 
excluded from 
the trial. 
 
0 Regimen of 
clopidogrel 
(Plavix) 75 
mg per/day) 
plus low-
dose ASA ( 
75-162mg 
per/day) 
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RESULTS 
This EBM review was completed on three randomized double-blinded controlled trials (RCTs). 
In the study by Diener the follow up period was 18 months, and the other two studies were a 28 
month period. Two of the articles used were presented with dichotomous data outcomes and one 
using continuous data. Medication dosed was the same for clopidogrel with the Aspirin dosage 
ranging from low dose of 75mg to 162mg or to placebo plus low dose aspirin in the Bhatt study 
and Hankey study, with follow up evaluations performed at 1, 3, 6 months and every 6 months 
thereafter until the end of the trial. In the Diener study patients were randomly allocated either 
75mg of clopidogrel with aspirin 75mg or a matching placebo tablet. This study continued for a 
total of 18 months with follow up visits at 1,3,6,12 and 18 months. All the patients in the studies 
used were 18 years of age or older.  For greater understanding of the calculations used in these 
articles it is important to understand the statistical calculations used to prove or disprove the 
efficacy of each study and intervention.  The efficacy rate for each intervention was calculated 
with clopidogrel and aspirin being the experimental event rate (EER) and placebo plus aspirin or 
placebo alone being the Controlled Event Rate (CER). The EER and CER was then used to 
calculate the Relative Benefit increase (RBI) and Absolute Benefit Increase (ABI). The ABI, 
which is interpreted as the absolute arithmetic difference in good outcomes between the 
experimental and control groups, was then used to calculate the Numbers Needed to Treat 
(NNT). This number is what is crucial to the provider and clinician as it demonstrates the 
number of patients needed to be treated in order to obtain one additional good outcome when 
being compared to the control medication.   For the data given as continuous data the test statistic 
was used to describe the method used to obtain the data in which a mRS score which 
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demonstrated the physical ability of the patient after having a stroke was used.  All three studies 
incorporated visually matched placebo in their analysis. The primary endpoint in all three studies 
was that of the first occurrence of an ischemic stroke or rehospitalization for an acute ischemic 
event.   
 In the Bhatt et al. 2006 study 15,603 patients with either clinically evident multiple 
atherosclerosis and established cardiovascular disease, or multiple risk factors received 
clopidogrel. Patients in this study had a mean age of 64 years old of which 29.8% were women. 
The groups divided were 7802 on clopidogrel plus aspirin and 7801 on visually matched placebo 
plus aspirin. Treatment was permanently discontinued by 20.4% of those in the clopidogrel 
group as compared with 18.2% in the placebo group giving a p-value of (P<0.001).  A total of 
4.8% of the patients in the clopidogrel group and 4.9% of those in the placebo group 
discontinued treatment because of an adverse event give a p-value of (P=0.67). Efficacy end 
point was completed in 99.5% of the patients of the patients randomly assigned to receive 
clopidogrel and aspirin and 99.6% of those randomly assigned to receive placebo and aspirin. 
The adverse event included the first occurrence of stroke as well as MI or cardiovascular cause. 
The efficacy end point results with a median of 28 months of follow up showed the primary 
event rate or EER to be 6.8% in the clopidogrel group and 7.3% in the placebo group the relative 
risk was 0.93 and a 95% CI, 0.83 to 1.05, the p-value was P=0.22. The first occurrence of stroke, 
TIA as well as other events such as MI, death from cardiovascular causes or hospitalization for 
unstable angina was 16.7% in the clopidogrel group and 17.9% in the placebo group. The 
relative risk was 0.92; 95% CI, 0.86 to 0.995; and a p-value of P=0.04. The rate of primary safety 
end points such as severe bleeding was 1.7% in the clopidogrel group and 1.3% in the placebo 
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group with a relative risk of 1.25%; 95% CI, 0.97 to 1.61; and a p-value of P=0.09. 1 The results 
are summarized in Table 2 and Table 3. 
In the Diener et al. 2004 study 7599 high risk patients with recent ischemic stroke or TIA in the 
previous 3 months. 3802 were allotted placebo and clopidogrel and 3797 aspirin and clopidogrel. 
In this study the efficacy end point results with a median of 18 months follow up showed the 
primary event rate or EER to be 15.7% in the clopidogrel group and 16.7% in the placebo and 
clopidogrel group. Relative risk was 6.4% and a 95% CI, (-4.6 to 16.3) the p-value being 
P=0.244.  Life-threatening bleedings were higher in groups receiving aspirin and clopidogrel 
versus those receiving placebo and clopidogrel which had an EER of 2.6 for the clopidogrel and 
aspirin and a CER of 1.3 the absolute risk increase ARI was 1.3 % with a 95% CI.2  
In the Hankey et al. study the modified Rankin Scale (mRS) score was also used at 3 months 
post stroke was assessed demonstrating the outcome of the functional severity of stroke. Among 
the 4320 patients who had a qualifying diagnosis of TIA or ischemic stroke for the study 233 
(5.4%) of them experienced a stoke during the follow up of whom 103 were randomly assigned 
clopidogrel and 130 placebo. The relative risk reduction was 20%, with a 95% CI: -3 % to 38%)  
Table 2: clopidogrel +Aspirin vs Placebo +Aspirin response 
 Clopidogrel
+Aspirin 
(EER) 
Placebo + 
aspirin 
(CER) 
P-value  RBI ABI NNT 
Bhatt DL  (2006) 28 
month trial  
6.8% 7.3% <0.22 -6.8% -0.5% -200a 
Diener HC (2004) 18 
month trial  
Clopidogrel 
+aspirin  
15.7% 
Placebo+ 
Clopidogrel  
16.7% 
P-Value  
<0.244 
RBI 
5.9% 
ABI 
-1% 
NNT 
- 100a 
a 95% Confidence Interval 
Table 3: mRS score of clopidogrel +Aspirin vs placebo + aspirin (dicotomous data) 
 Clopidogrel 
+Aspirin 
 
Placebo + aspirin  
 
P-value  
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Hankey study  
mRS score of 1-2 
showed  no symptoms or no significant disability 
to death 
44% 46% P = 0.59 
95% CI  - 3% to 38% 
 
In this review of all three studies the safety, tolerability as well as the serious of adverse effects 
with use of clopidogrel and aspirin. This was calculated using dichotomous data in two of the 
studies. The third study by Hankey assessed severity or harm by use of the mRS score. 3 Tables 
4 and 5 summarize the results of these studies.   
Table 4: Severe adverse effects data for clopidogrel and aspirin 
 Clopidogrel 
+ aspirin  
(EER) 
Placebo + 
aspirin  
(CER) 
Relative 
Risk 
Increase 
(RRI) 
Absolute 
Risk 
Increase 
(ABI) 
Number 
needed to 
harm 
(NNH) 
P-value 
Bhatt DL  
(2006) 28 
month trial 
1.7% 1.3% 30.7% 0.4% 250 
patients 
0.09 
Diener HC 
(2004) 18 
month trial 
2.6% 1.3% 1% 1.3% 77 patients <0.0001 
Both with a 95% CI  
Table5: Severe adverse effects for clopidogrel and aspirin using mRS score (continuous data) 
  Number ischemic strokes with 
use of clopidogrel +aspirin 
202/233 patients  
Number of hemorrhagic 
storkes with use of clopidogrel 
+ aspirin  19/236 patients  
Hankey study  
mRS score 
87% 8% 
 
DISCUSSION 
 The major goal of therapy in patients who have experienced a stroke is to prevent a 
recurrent stroke and even more so other adverse life altering effects. Antiplatelet and 
antithrombotic therapy have had significant results in both the treatment and prevention of 
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stroke.  In most patients the effectiveness of aspirin alone in preventing antithrombotic events has 
been well studied and proved to have great efficacy. Clopidogrel as a single therapy in the 
prevention of stroke has also been well studied but has not been proven to have significant 
benefit in the prevention of stroke.  In these studies it was found that the addition of aspirin to 
clopidogrel had a consistent reduction in primary and secondary vascular events but the 
difference between the combination therapy as compared to single antithrombotic therapy was 
not significant. It was also seen that in patients with established artherothrombotic disease or 
who were at high risk for such disease there was no benefit associated with the combination 
therapy of clopidogrel and aspirin in reducing the incidence of stroke. The most significant 
finding in this study was that the rate of severe bleeding was increased. The most major type of 
life-threatening bleeding that was noted was gastrointestinal bleeding as well as intracranial 
bleeding in the Diener et al. study.    
Although all three studies were able to analyze and prove that there was little to no significance 
of prevention in stroke with the use of combination therapy of clopidogrel (Plavix) and aspirin  
there were still some limitations found in the studies used.  In the Hankey et al study although 
the hypothesis and analysis for the clinical trial were prespecified it was a substudy and not the 
primary aim of the trial. Patients were included in this analysis of stroke severity on the basis of 
an end point and therefore it is not possible to assume that at the beginning of the trial there was 
an equal balance in important prognostic factors between the treatment groups. Another 
limitation within this study was that the modified Rankin Scale (mRS) which was used to 
measure the severity of the stroke with use of activities of daily living was not assessed at the 
time of randomization (i.e at baseline) introducing a possibility of there being an imbalance in 
the functional status of patients at baseline. In Bhatt et al study the primary end point of the study 
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was not primarily stroke but also included myocardial infarction, or death from cardiovascular 
causes therefore not making the primary focus of the study stroke and also decreasing the actual 
sample size of those in the trial with an end point of stroke. The trial also did not allow for a 
measurement or baseline before randomization of the study to accurately be able to determine the 
severity once randomization of the trial had begun leading to questioning of statistical data.   
CONCLUSION 
 Therefore in conclusion as shown in previous studies all patients experiencing a stroke or 
TIA should receive an antiplatelet drug for secondary stroke prevention. Current guidelines favor 
clopidogrel or aspirin but as show with the three randomized control studies the combination of 
clopidogrel plus aspirin was not significantly more effective than single antiplatelet or 
antithrombotic therapy in the prevention of stroke. Furthermore the risk of moderate to severe 
bleeding was increased in all three studies showing no evidence of support in the use of dual 
antiplatelet therapy. In conclusion future studies should include randomized controlled trials with 
larger sample size and most importantly should begin with a baseline measurement of activities 
of daily living patients can do before randomization of the trial has begun. This will allow for a 
more accurate statistical significance.  Due to the risk of associated bleeding that occurs with 
dual antiplatelet interesting future studies could include looking further into patients with pre-
established vascular disease who possibly represent those with hyperactive platelets. If this is 
concept is found to be true, dual antiplatelet therapy would be associated with greater efficacy 
and a lower rate of bleeding in a patients who are symptomatic and less efficacious in patients 
with a reduced basal platelet activity who are asymptomatic which would therefore increase the 
risk of bleeding complications. However with the current studies and data until proven otherwise 
clinicians should avoid dual antiplatelet therapy in the prevention of stroke.
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